Search research articles
Contact Us
Filters
Showing results (41-50 of 168) with videos related to
Page
of 17
Sort By:
The Journal of Biological Chemistry
|
October 16, 2001
Metalloprotease-dependent protransforming growth factor-alpha ectodomain shedding in the absence of tumor necrosis factor-alpha-converting enzyme
A Merlos-Suárez, S Ruiz-Paz, J Baselga, et al.
Oncology (Williston Park, N.Y.)
|
March 1, 1997
HER2 overexpression and paclitaxel sensitivity in breast cancer: therapeutic implications
J Baselga, A D Seidman, P P Rosen, et al.
Journal of Colloid and Interface Science
|
October 14, 2003
Kinetic study of epoxy curing in the glass fiber/epoxy interface using dansyl fluorescence
D Olmos, A J Aznar, J Baselga, et al.
Journal of Cell Science
|
February 26, 1999
The cytoplasmic carboxy-terminal amino acid determines the subcellular localization of proTGF-(alpha) and membrane type matrix metalloprotease (MT1-MMP)
J M Ureña, A Merlos-Suárez, J Baselga, et al.
Medicina Clinica
|
April 30, 1985
[Value of the electrophysiologic study of the diaphragm in the diagnosis of phrenic paralysis]
J Martínez Pérez, J Baselga, E Monsó, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 24, 2010
Formulary availability and regulatory barriers to accessibility of opioids for cancer pain in Europe: a report from the ESMO/EAPC Opioid Policy Initiative
N I Cherny, J Baselga, F de Conno, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 29, 2009
Status of PI3K inhibition and biomarker development in cancer therapeutics
B Markman, F Atzori, J Pérez-García, et al.
Cancer Research
|
July 14, 1998
Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts
J Baselga, L Norton, J Albanell, et al.
The Journal of Biological Chemistry
|
September 12, 1998
Pro-tumor necrosis factor-alpha processing activity is tightly controlled by a component that does not affect notch processing
A Merlos-Suárez, J Fernández-Larrea, P Reddy, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 10, 2019
Pooled analysis of cardiac safety in patients with cancer treated with pertuzumab
D Lenihan, T Suter, M Brammer, et al.
Page
of 17
Search research articles
Search
Showing results (41-50 of 168) with videos related to
Sort By:
Page
of 17
The Journal of Biological Chemistry
|
October 16, 2001
Metalloprotease-dependent protransforming growth factor-alpha ectodomain shedding in the absence of tumor necrosis factor-alpha-converting enzyme
A Merlos-Suárez, S Ruiz-Paz, J Baselga, et al.
Oncology (Williston Park, N.Y.)
|
March 1, 1997
HER2 overexpression and paclitaxel sensitivity in breast cancer: therapeutic implications
J Baselga, A D Seidman, P P Rosen, et al.
Journal of Colloid and Interface Science
|
October 14, 2003
Kinetic study of epoxy curing in the glass fiber/epoxy interface using dansyl fluorescence
D Olmos, A J Aznar, J Baselga, et al.
Journal of Cell Science
|
February 26, 1999
The cytoplasmic carboxy-terminal amino acid determines the subcellular localization of proTGF-(alpha) and membrane type matrix metalloprotease (MT1-MMP)
J M Ureña, A Merlos-Suárez, J Baselga, et al.
Medicina Clinica
|
April 30, 1985
[Value of the electrophysiologic study of the diaphragm in the diagnosis of phrenic paralysis]
J Martínez Pérez, J Baselga, E Monsó, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 24, 2010
Formulary availability and regulatory barriers to accessibility of opioids for cancer pain in Europe: a report from the ESMO/EAPC Opioid Policy Initiative
N I Cherny, J Baselga, F de Conno, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 29, 2009
Status of PI3K inhibition and biomarker development in cancer therapeutics
B Markman, F Atzori, J Pérez-García, et al.
Cancer Research
|
July 14, 1998
Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts
J Baselga, L Norton, J Albanell, et al.
The Journal of Biological Chemistry
|
September 12, 1998
Pro-tumor necrosis factor-alpha processing activity is tightly controlled by a component that does not affect notch processing
A Merlos-Suárez, J Fernández-Larrea, P Reddy, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 10, 2019
Pooled analysis of cardiac safety in patients with cancer treated with pertuzumab
D Lenihan, T Suter, M Brammer, et al.
Page
of 17